IP Verse

Recombinant Rsv Antigens - EP3109258

The patent EP3109258 was granted to Glaxosmithkline on Jan 23, 2019. The application was originally filed on Dec 23, 2008 under application number EP16180926A. The patent is currently recorded with a legal status of "Revoked".

EP3109258

GLAXOSMITHKLINE
Application Number
EP16180926A
Filing Date
Dec 23, 2008
Status
Revoked
Dec 1, 2023
Publication Date
Jan 23, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

JANSSEN VACCINES & PREVENTIONOct 23, 2019MEWBURN ELLIS -
PFIZEROct 23, 2019PFIZER -

Patent Citations (52) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0109942
DESCRIPTIONEP0362279
DESCRIPTIONEP0689454
DESCRIPTIONEP0729473
DESCRIPTIONGB2220211
DESCRIPTIONUS2003044425
DESCRIPTIONUS2005042230
DESCRIPTIONUS2007178469
DESCRIPTIONUS2008300382
DESCRIPTIONUS4235877
DESCRIPTIONUS4372945
DESCRIPTIONUS4436727
DESCRIPTIONUS4474757
DESCRIPTIONUS4707543
DESCRIPTIONUS4866034
DESCRIPTIONUS4877611
DESCRIPTIONUS4912094
DESCRIPTIONUS5057540
DESCRIPTIONUS5149650
DESCRIPTIONUS5194595
DESCRIPTIONUS5278302
DESCRIPTIONUS5666153
DESCRIPTIONUS5726292
DESCRIPTIONUS5856462
DESCRIPTIONUS5985284
DESCRIPTIONUS6005099
DESCRIPTIONUS6113911
DESCRIPTIONUS6303347
DESCRIPTIONUS6764840
DESCRIPTIONUS7368537
DESCRIPTIONWO0000462
DESCRIPTIONWO0146127
DESCRIPTIONWO02074969
DESCRIPTIONWO02085905
DESCRIPTIONWO03011223
DESCRIPTIONWO03043572
DESCRIPTIONWO03099195
DESCRIPTIONWO2004071459
DESCRIPTIONWO2008114149
DESCRIPTIONWO9421292
DESCRIPTIONWO9514026
DESCRIPTIONWO9526204
DESCRIPTIONWO9602555
DESCRIPTIONWO9611711
DESCRIPTIONWO9633739
DESCRIPTIONWO9850399
DESCRIPTIONWO9933488
DESCRIPTIONWO9964301
OPPOSITIONUS5194595
OPPOSITIONWO2008114149
OPPOSITIONWO2008154456
SEARCHWO2006042156

Non-Patent Literature (NPL) Citations (83) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- ALTSCHUL ET AL., J. MOL. BIOL., (1990), vol. 215, page 403
DESCRIPTION- ALTSCHUL ET AL., NATURE GENET., (1994), vol. 6, page 119
DESCRIPTION- BENJAMIN LEWIN, Genes V, OXFORD UNIVERSITY PRESS, (1994), ISBN 0-19-854287-9
DESCRIPTION- BIOCHEMISTRY, (1997), vol. 36, pages 10230 - 10239
DESCRIPTION- BITTER ET AL., METHODS IN ENZYMOL, (1987), vol. 153, pages 516 - 544
DESCRIPTION- BOMFORD ET AL., VACCINE, (1992), vol. 10, no. 9, pages 572 - 577
DESCRIPTION- CALDER ET AL., VIROLOGY, (2000), vol. 271, pages 122 - 131
DESCRIPTION- CONNOLLY ET AL., PROC. NATL. ACAD. SCI. USA, (2006), vol. 103, pages 17903 - 17908
DESCRIPTION- CORPET ET AL., NUCLEIC ACIDS RESEARCH, (1988), vol. 16, page 10881
DESCRIPTION- EUR. J. BIOCHEM., (2004), vol. 271, pages 4284 - 4292
DESCRIPTION- E. W. MARTIN, Remington's Pharmaceutical Sciences, 5th ed., MACK PUBLISHING CO.
DESCRIPTION- GIROD ET AL., NATURE METHODS, (2007), vol. 4, pages 747 - 753
DESCRIPTION- GRANT ET AL., METHODS IN ENZYMOLOGY, (1987), vol. 153, pages 516 - 544
DESCRIPTION- HARBURY ET AL., SCIENCE, (1993), vol. 262, pages 1401 - 1407
DESCRIPTION- HIGGINS; SHARP, CABIOS, (1989), vol. 5, page 151
DESCRIPTION- HIGGINS; SHARP, GENE, (1988), vol. 73, page 237
DESCRIPTION- KAISHO; AKIRA, BIOCHIMICA ET BIOPHYSICA ACTA, (2002), vol. 1589, pages 1 - 13
DESCRIPTION- KENDREW ET AL., The Encyclopedia of Molecular Biology, BLACKWELL SCIENCE LTD, (1994), ISBN 0-632-02182-9
DESCRIPTION- KENSIL, C. R., "Saponins as vaccine adjuvants", CRIT REV THER DRUG CARRIER SYST, (1996), vol. 12, no. 1-2, pages 1 - 55
DESCRIPTION- LACAILLE-DUBOIS, M; WAGNER H, "A review of the biological and pharmacological activities of saponins", PHYTOMEDICINE, (1996), vol. 2, pages 363 - 386
DESCRIPTION- LEVITSKY ET AL., BIOINFORMATICS, (1999), vol. 15, pages 582 - 592
DESCRIPTION- LOWELL ET AL., J. EXP. MED., (1988), vol. 167, page 658
DESCRIPTION- LOWELL ET AL., SCIENCE, (1988), vol. 240, page 800
DESCRIPTION- LOWELL GH, "Proteosomes for Improved Nasal, Oral, or Injectable Vaccines", LOWELL GH, LEVINE MM, WOODROW GC, KAPER JB, COBON GS, New Generation Vaccines, MARCEL DEKKER, INC., (1997), pages 193 - 206
DESCRIPTION- LOWELL, New Generation Vaccines, 2nd ed., MARCEL DEKKER, INC., (1997), page 193
DESCRIPTION- LYNCH ET AL., BIOPHYS. J., (1984), vol. 45, page 104
DESCRIPTION- MORTON ET AL., VIROLOGY, vol. 311, pages 275 - 288
DESCRIPTION- NEEDLEMAN; WUNSCH, J. MOL. BIOL., (1970), vol. 48, page 443
DESCRIPTION- OTTE ET AL., BIOTECHNOL. PROG., (2007), vol. 23, pages 801 - 807
DESCRIPTION- PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, page 2444
DESCRIPTION- "Pharmaceutical Biotechnology", POWELL AND NEWMAN, Vaccine Design-the subunit and adjuvant approach, PLENUM PRESS, (1995), vol. 61
DESCRIPTION- RESULTS PROBL CELL DIFFER, (1994), vol. 20, pages 125 - 62
DESCRIPTION- ROBERT A. MEYERS, Molecular Biology and Biotechnology: a Comprehensive Desk Reference, VCH PUBLISHERS, INC., (1995), ISBN 1-56081-569-8
DESCRIPTION- SABROE ET AL., JI, (2003), pages 1630 - 5
DESCRIPTION- SMITH; WATERMAN, ADV. APPL. MATH., (1981), vol. 2, page 482
DESCRIPTION- "Vaccine Design-the subunit and adjuvant approach", POWELL AND NEWMAN, Pharmaceutical Biotechnology, PLENUM PRESS, (1995), vol. 61
DESCRIPTION- VAN HEEKE; SCHUSTER, J BIOL CHEM, (1989), vol. 264, pages 5503 - 5509
DESCRIPTION- WALKER; 1996, The Protein Protocols Handbook, HUMANA PRESS
DESCRIPTION- ZHANG; HENZEL, PROTEIN SCI., (2004), vol. 13, pages 2819 - 2824
EXAMINATION- J. S. MCLELLAN ET AL, "Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus", SCIENCE, (20131101), vol. 342, no. 6158, doi:10.1126/science.1243283, ISSN 0036-8075, pages 592 - 598, XP055391357
OPPOSITION- CONNORS M et al., "RESPIRATORY SYNCYTIAL VIRUS (RSV) F, G, M2 (22K), AND N PROTEINS EACH INDUCE RESISTANCE TO RSV CHALLENGE, BUT RESISTANCE INDUCED BY M2 AND N PROTEINS IS RELATIVELY SHORT-LIVED", JOURNAL OF VIROLOGY, (19910300), vol. 65, no. 3, pages 1634 - 1637, XP002047927
OPPOSITION- Dudas and Karron, "Respiratory syncytial virus vaccines", CLINICAL MICROBIOLOGY REVIEWS, (199807), vol. 11, no. 3, pages 430 - 439, XP002154718
OPPOSITION- Russel and Luque, "The structural basis of paramyxovirus invasion", TRENDS IN MICROBIOLOGY, (200606), vol. 14, no. 6, pages 243 - 246, XP005486346
OPPOSITION- RUSSELL CJ et al., "The structural basis of paramyxovirus invasion", TRENDS IN MICROBIOLOGY, (200606), vol. 14, no. 6, pages 243 - 246, XP005486346
OPPOSITION- WERTZ GW et al., "EXPRESSION OF THE FUSION PROTEIN OF HUMAN RESPIRATORY SYNCYTIAL VIRUS FROM RECOMBINANT VACCINIA VIRUS VECTORS AND PROTECTION OF VACCINATED MICE", J Virol., (19870200), vol. 61, no. 2, pages 293 - 301, XP002018436
OPPOSITION- SASTRE P et al., "Comparison of affinity chromatography and adsorption to vaccinia virus recombinant infected cells for depletion of antibodies directed against respiratory syncytial virus glycoproteins present in a human immunoglobulin preparation", J Med Virol., (20050600), vol. 76, no. 2, pages 248 - 255, XP002444395
OPPOSITION- VAN DRUNEN LITTEL -VAN DEN HURK et al., "Immunopathology of RSV infection: prospects for developing vaccines without this complication", REVIEWS IN MEDICAL VIROLOGY, (20070000), vol. 17, pages 5 - 34, XP002510797
OPPOSITION- GRAHAM BS et al., "Novel antigens for RSV vaccines", Current Opinion in Immunology, (20150800), vol. 35, pages 30 - 8, XP055654465
OPPOSITION- Lamb and Jardetzky, "Structural basis of viral invasion: lessons from paramyxovirus F", Current Opinion in Structural Biology, (200708), vol. 17, no. 4, pages 427 - 436, XP022273654
OPPOSITION- SINGH et al., "Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model", Vaccine, (20070000), vol. 25, no. 33, pages 6211 - 6223, XP022168621
OPPOSITION- Yin et al, "Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation", Nature, (20060105), vol. 439, pages 38 - 44, XP002503490
OPPOSITION- YIN HS et al., "Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation", Nature, (20060105), vol. 439, no. 7072, pages 38 - 44, XP002503490
OPPOSITION- Yin et al, "002503489", PNAS, (20050628), vol. 102, no. 26, pages 9288 - 9293, XP002503489
OPPOSITION- YIN HS et al., "Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein", PNAS, (20050628), vol. 102, no. 26, pages 9288 - 9293, XP002503489
OPPOSITION- Connolly et al, "Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy", PNAS, (20061121), vol. 103, no. 47, pages 17903 - 17908, XP002503488
OPPOSITION- CONNOLLY SA et al., "Refolding of a paramyxovirus F protein from prefusion to postfusion conformations observed by liposome binding and electron microscopy", PNAS, (20061121), vol. 103, no. 47, pages 17903 - 17908, XP002503488
OPPOSITION- SWANSON KA et al., "Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers", PNAS, (20110607), vol. 108, no. 23, pages 9619 - 9624, XP055032519
OPPOSITION- GONZALEZ-REYES et al., "Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion", PNAS, (20010814), vol. 98, no. 17, pages 9859 - 9864, XP008136810
OPPOSITION- GONZALEZ-REYES L et al., "Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion", PNAS, (20010814), vol. 98, no. 17, pages 9859 - 9864, XP008136810
OPPOSITION- Zhao et al., "Structural characterization of the human respiratory syncytial virus fusion protein core", PNAS, (20001219), vol. 97, no. 26, pages 14172 - 14177, XP002431420
OPPOSITION- BELSHE RB et al., "Immunogenicity of Purified F Glycoprotein of Respiratory Syncytial Virus: Clinical and Immune Responses to Subsequent Natural Infection in Children", The Journal of Infectious Diseases, (199310), vol. 168, no. 4, pages 1024 - 1029, XP055652864
OPPOSITION- SCHWARZ TF et al., "Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial", J Infect Dis., (20190816), XP055654468
OPPOSITION- PIEDRA PA, "Clinical experience with respiratory syncytial virus vaccines", Pediatr Infect Dis J., (20030200), vol. 22, no. 2, pages S94 - S99, XP008166766
OPPOSITION- MARTIN et al., "Sequence elements of the fusion peptide of human respiratory syncytial virus fusion protein required for activity", JOURNAL OF GENERAL VIROLOGY, (20060000), vol. 87, pages 1649 - 1658, XP002600413
OPPOSITION- McLellan et al, "Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody", Science, (20130531), vol. 340, pages 1113 - 1117, XP055077617
OPPOSITION- MCLELLAN JS et al., "Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing Antibody", Science, (20130531), vol. 340, no. 6136, pages 1113 - 1117, XP055077617
OPPOSITION- MCLELLAN JS et al., "Structure-Based Design of a Fusion Glycoprotein Vaccine for Respiratory Syncytial Virus", Science, (20131101), vol. 342, no. 6158, pages 592 - 598, XP055132637
OPPOSITION- CRANK MC et al., "A proof of concept for structure-based vaccine design targeting RSV in humans", Science, (20190802), vol. 365, no. 6452, pages 505 - 509, XP055654466
OPPOSITION- NGWUTA JO et al., "Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera", Science Translational Medicine, (20151014), vol. 7, no. 309, XP055265885
OPPOSITION- Swanson et al, "A Monomeric Uncleaved Respiratory Syncytial Virus F Antigen Retains Prefusion-Specific Neutralizing Epitopes", Journal of Virology, (201410), vol. 88, no. 20, pages 11802 - 11810, XP008174055
OPPOSITION- Blais et al, "Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation", JOURNAL OF VIROLOGY, (201707), vol. 91, no. 13, pages 1 - 18, XP055652858
OPPOSITION- Yang et al, "MODIFICATIONS THAT STABILIZE HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE GLYCOPROTEIN TRIMERS IN SOLUTION", JOURNAL OF VIROLOGY, (200005), vol. 74, no. 10, pages 4746 - 4754, XP002939088
OPPOSITION- Yang et al, "Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin", JOURNAL OF VIROLOGY, (200205), vol. 76, no. 9, pages 4634 - 4642, XP002321404
OPPOSITION- RIGTER A et al., "A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant Prefusion-Like Form of the F Protein Bound to Bacterium-Like Particles", PLoS One, (20130812), vol. 8, no. 8, pages 1 - 14, XP002718926
OPPOSITION- Rigter et al, "A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant Prefusion-Like Form of the F Protein Bound to Bacterium-Like Particles", PLOS ONE, (201308), vol. 8, no. 8, pages 1 - 14, XP002718926
OPPOSITION- Widjaja et al, "Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics", PLOS ONE, (20150624), pages 1 - 19, XP009186476
OPPOSITION- WIDJAJA I et al., "Recombinant Soluble Respiratory Syncytial Virus F Protein That Lacks Heptad Repeat B, Contains a GCN4 Trimerization Motif and Is Not Cleaved Displays Prefusion-Like Characteristics", PLoS One, (20150624), vol. 10, no. 6, pages 1 - 19, XP009186476
SEARCH- SASTRE PATRICIA ET AL, "Comparison of affinity chromatography and adsorption to vaccinia virus recombinant infected cells for depletion of antibodies directed against respiratory syncytial virus glycoproteins present in a human immunoglobulin preparation", JOURNAL OF MEDICAL VIROLOGY, JOHN WILEY & SONS, INC, US, (20050601), vol. 76, no. 2, doi:10.1002/JMV.20349, ISSN 0146-6615, pages 248 - 255, XP002444395 [X] 1,2,5,9,11,13,16,17 * p. 249, Viruses and cells; p. 253, left-hand column * [Y] 3,4,6-8,10,12,14,15
SEARCH- VAN DRUNEN LITTEL-VAN DEN HURK S ET AL, "Immunopathology of RSV infection: prospects for developing vaccines without this complication", REVIEWS IN MEDICAL VIROLOGY, CHICHESTER, GB, vol. 17, no. 1, doi:10.1002/RMV.518, ISSN 1052-9276, (20070927), pages 5 - 34, (20060927), XP002510797 [Y] 1-17 * page 16, column l, paragraph 2 - page 19, column r, paragraph 1 *
SEARCH- SINGH ET AL, "Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model", VACCINE, ELSEVIER LTD, GB, (20070724), vol. 25, no. 33, doi:10.1016/J.VACCINE.2007.05.068, ISSN 0264-410X, pages 6211 - 6223, XP022168621 [Y] 1-17 * abstract *
SEARCH- M. MAGRO ET AL, "Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (20120221), vol. 109, no. 8, doi:10.1073/pnas.1115941109, ISSN 0027-8424, pages 3089 - 3094, XP055067859 [T] * the whole document *
SEARCH- LUIS GONZÁLEZ-REYES ET AL, "Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, (20010814), vol. 98, no. 17, doi:10.1073/PNAS.151098198, ISSN 0027-8424, pages 9859 - 9864, XP008136810 [X] 1,8,11-13,16,17 * abstract; p. 9864, left-hand column; fig. 1B; p. 9861, right-hand column; p. 9860, left-hand column; discussion, last paragraph * [Y] 2-7,9,10,14,15
SEARCH- DIANA MART N ET AL, "Sequence elements of the fusion peptide of human respiratory syncytial virus fusion protein required for activity", JOURNAL OF GENERAL VIROLOGY, SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD, GB, (2006), vol. 87, doi:10.1099/VIR.0.81715-0, ISSN 0022-1317, pages 1649 - 1658, XP002600413 [X] 1,2,5,6,8,11,13 * fig. 1;methods, p. 1651; p. 1652, left-hand column; p. 1654; figs. 3-4 * [Y] 3,4,7,9,10,12,14-17

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents